These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
126 related articles for article (PubMed ID: 3134309)
1. Correlation between urokinase-type plasminogen activator production and the metastasizing ability of two murine mammary adenocarcinomas. Pereyra-Alfonso S; Haedo A; Bal de Kier Joffé E Int J Cancer; 1988 Jul; 42(1):59-63. PubMed ID: 3134309 [TBL] [Abstract][Full Text] [Related]
2. Urokinase-type plasminogen activator activity increases during the growth of two murine mammary adenocarcinomas with different metastasizing abilities. Pereyra-Alfonso S; Solarz GR; Bal de Kier Joffé E Clin Exp Metastasis; 1992 Nov; 10(6):395-401. PubMed ID: 1451349 [TBL] [Abstract][Full Text] [Related]
3. Varying patterns of expression of insulin-like growth factors I and II and their receptors in murine mammary adenocarcinomas of different metastasizing ability. Guerra FK; Eijan AM; Puricelli L; Alonso DF; Bal de Kier Joffé E; Kornblihgtt AR; Charreau EH; Elizalde PV Int J Cancer; 1996 Mar; 65(6):812-20. PubMed ID: 8631597 [TBL] [Abstract][Full Text] [Related]
4. Impairment of fibrinolysis during the growth of two murine mammary adenocarcinomas. Alonso DF; Farías EF; Bal de Kier Joffé E Cancer Lett; 1993 Jul; 70(3):181-7. PubMed ID: 8353814 [TBL] [Abstract][Full Text] [Related]
5. Purification and characterization of an inhibitor of plasminogen activator released by rat mammary adenocarcinoma cells. Grant AJ; Ramshaw IA; Badenoch-Jones P; Eichner RD; Hunt NH Eur J Biochem; 1986 Feb; 154(3):635-41. PubMed ID: 3081343 [TBL] [Abstract][Full Text] [Related]
6. Effects of in vivo culture of murine mammary adenocarcinoma cells on tumor and metastatic growth. Aguirre Ghiso J; Diament M; D'elia I; Bal de Kier Joffé E; Klein S Tumour Biol; 1997; 18(1):41-52. PubMed ID: 8989924 [TBL] [Abstract][Full Text] [Related]
7. Protease activity of urokinase and tumor progression in a syngeneic mammary cancer model. Merchan JR; Tang J; Hu G; Lin Y; Mutter W; Tong C; Karumanchi SA; Russell SJ; Sukhatme VP J Natl Cancer Inst; 2006 Jun; 98(11):756-64. PubMed ID: 16757700 [TBL] [Abstract][Full Text] [Related]
8. Relationship between secreted urokinase plasminogen activator activity and metastatic potential in murine B16 cells transfected with human urokinase sense and antisense genes. Yu HR; Schultz RM Cancer Res; 1990 Dec; 50(23):7623-33. PubMed ID: 1701350 [TBL] [Abstract][Full Text] [Related]
9. Soluble factors released by the target organ enhance the urokinase-type plasminogen activator activity of metastatic tumor cells. Bal de Kier Joffé E; Alonso DF; Puricelli L Clin Exp Metastasis; 1991; 9(1):51-6. PubMed ID: 2015717 [TBL] [Abstract][Full Text] [Related]
10. Fibrin formation induced by tumor procoagulants enhances urokinase activity produced by mammary carcinoma cells. Alonso DF; De Lorenzo MS; Tejera AM; Gomez DE Oncol Rep; 1998; 5(1):209-12. PubMed ID: 9458324 [TBL] [Abstract][Full Text] [Related]
11. Constitutive expression and secretion of proteases in non-metastatic SP1 mammary carcinoma cells and its metastatic sublines. Korczak B; Kerbel RS; Dennis J Int J Cancer; 1991 Jun; 48(4):557-61. PubMed ID: 2045200 [TBL] [Abstract][Full Text] [Related]
12. Relationship between circulating plasminogen activators and tumor development in mice. Colombi M; Rebessi L; Boiocchi M; Barlati S Cancer Res; 1986 Nov; 46(11):5748-53. PubMed ID: 3093069 [TBL] [Abstract][Full Text] [Related]
13. Production of protease inhibitors by postsurgical macrophages. Fukasawa M; Campeau JD; Girgis W; Bryant SM; Rodgers KE; DiZerega GS J Surg Res; 1989 Mar; 46(3):256-61. PubMed ID: 2493532 [TBL] [Abstract][Full Text] [Related]
14. Synthesis and secretion of plasminogen activators and plasminogen activator inhibitors in cell lines of different groups of human lung tumors. Heidtmann HH; Hofmann M; Jacob E; Erbil C; Havemann K; Schwartz-Albiez R Cancer Res; 1989 Dec; 49(24 Pt 1):6960-5. PubMed ID: 2555056 [TBL] [Abstract][Full Text] [Related]
15. Human synovial fibroblasts produce urokinase-type plasminogen activator. Medcalf RL; Hamilton JA Arthritis Rheum; 1986 Nov; 29(11):1397-401. PubMed ID: 3096341 [TBL] [Abstract][Full Text] [Related]
16. In vitro urokinase type plasminogen activator levels and total plasminogen activator activity in squamous cell carcinomas of the head and neck. Petruzzelli GJ; Snyderman CH; Johnson JT Arch Otolaryngol Head Neck Surg; 1994 Sep; 120(9):989-92. PubMed ID: 8074827 [TBL] [Abstract][Full Text] [Related]
17. Stimulated production of urokinase and plasminogen activator inhibitor-2 by the human promyelocytic leukemia cell line HL-60. Alving BM; Krishnamurti C; Liu YP; Lucas DL; Wright DG Thromb Res; 1988 Jul; 51(2):175-85. PubMed ID: 3142093 [TBL] [Abstract][Full Text] [Related]
18. Correlation between urokinase-type plasminogen activator production and the metastatic ability of human rectal cancer cells. Marutsuka K; Suzumiya J; Kataoka H; Komada N; Koono M; Sumiyoshi A Invasion Metastasis; 1991; 11(4):181-91. PubMed ID: 1765431 [TBL] [Abstract][Full Text] [Related]
20. Enhanced plasminogen activator production by highly metastatic variant cell lines of a rat mammary adenocarcinoma. Ramshaw IA; Badenoch-Jones P; Grant A; Maxted M; Claudianos C Invasion Metastasis; 1986; 6(3):133-44. PubMed ID: 3733365 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]